Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 4/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877612 | 0.86 | SLC6A9 (0.41) | ACLY | |
| SCHEMBL23877538 | 0.83 | ACLY (0.35) | ACLYMCL1KCNA5 | |
| SCHEMBL23879620 | 0.77 | CYP2C9 (0.46) | ACLYMETAP2MCL1AVPR2GPR27 | |
| SCHEMBL23877551 | 0.76 | ALDH1A1 (0.48) | ALDH1A1HPGDHSD17B10GPR27 | |
| SCHEMBL23877436 | 0.72 | KMT2A (0.36) | ACLYMCL1AVPR2GPR27 | |
| SCHEMBL23877434 | 0.71 | AVPR2 (0.42) | METAP2KCNA5ALDH1A1AVPR2GPR27 | |
| SCHEMBL23877557 | 0.71 | ACLY (0.39) | ACLYMCL1 | |
| SCHEMBL23879573 | 0.70 | KDM4E (0.39) | ACLYALDH1A1HPGDHSD17B10MMP2 | |
| SCHEMBL31046897 | 0.69 | BCAT2 (0.39) | ALDH1A1HPGDAVPR2GPR27 | |
| SCHEMBL23877507 | 0.67 | KCNA5 (0.43) | KCNA5ALDH1A1HPGDHSD17B10CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | ACLY 2228/4885METAP2 2660/4885MCL1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.